Isis Pharmaceuticals Gets $10M From Biogen Idec

Carlsbad-based Isis Pharmaceuticals, which is developing antisense technology for a wide range of conditions, said it has earned $10M in a milestone payment from Biogen Idec today. Isis Pharmaceuticals said the payment is associated with the validation of an undisclosed target to treat a neurological disorder. The two have multiple programs together, where Biogen Idec is tapping Isis PHarmceuticals' antisense technology.